Literature DB >> 22113135

The obstetric management of sickle cell disease.

Jo Howard1, Eugene Oteng-Ntim.   

Abstract

Sickle cell disease (SCD) is the most common inherited disease worldwide and is associated with anaemia and intermittent severe pain. Pregnant women who are affected have increased maternal and fetal mortality and morbidity. In view of this obstetricians should have an awareness of this condition and its complications, and pregnancies in women with SCD should be managed by a multidisciplinary team with experience of high risk pregnancies. Ideally women should be seen preconceptually for optimisation of their SCD and partner screening. Antenatal care should include regular outpatient visits with regular monitoring for pre-eclampsia and of fetal growth. Blood transfusion should be used for the treatment of acute anaemia, acute chest syndrome or acute stroke but there is not sufficient evidence currently to recommend its use prophylactically. There is an increased prevalence of sickle crisis during pregnancy and patients should be monitored carefully throughout this time.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22113135     DOI: 10.1016/j.bpobgyn.2011.10.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  20 in total

1.  Reproductive health choices for young adults with sickle cell disease or trait: randomized controlled trial immediate posttest effects.

Authors:  Diana J Wilkie; Agatha M Gallo; Yingwei Yao; Robert E Molokie; Christine Stahl; Patricia E Hershberger; Zhongsheng Zhao; Marie L Suarez; Robert J Labotka; Bonnye Johnson; Rigo Angulo; Veronica Angulo; Jesus Carrasco; David Shuey; Stephanie Pelligra; Edward Wang; Dennie T Rogers; Alexis A Thompson
Journal:  Nurs Res       Date:  2013 Sep-Oct       Impact factor: 2.381

2.  Different morphological and gene expression profile in placentas of the same sickle cell anemia patient in pregnancies of opposite outcomes.

Authors:  Letícia C Baptista; Camilla O Figueira; Bruno B Souza; Kleber Y Fertrin; Arthur Antolini; Fernando F Costa; Mônica B de Melo; Maria Laura Costa
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-28

3.  Sickle cell disease in pregnancy: maternal complications in a Medicaid-enrolled population.

Authors:  Sheree L Boulet; Ekwutosi M Okoroh; Ijeoma Azonobi; Althea Grant; W Craig Hooper
Journal:  Matern Child Health J       Date:  2013-02

4.  Acute pain crisis in a patient with sickle cell disease undergoing ovarian simulation for fertility preservation prior to curative stem cell transplantation: case report and literature review.

Authors:  Michelle Matthews; Rebecca Pollack
Journal:  J Assist Reprod Genet       Date:  2017-08-11       Impact factor: 3.412

Review 5.  Management of sickle cell disease in the community.

Authors:  Valentine Brousse; Julie Makani; David C Rees
Journal:  BMJ       Date:  2014-03-10

6.  Perceptions of young adults with sickle cell disease concerning their disease experience.

Authors:  Nadine Matthie; Jill Hamilton; Diana Wells; Coretta Jenerette
Journal:  J Adv Nurs       Date:  2015-09-09       Impact factor: 3.187

7.  Complications in pregnant women with sickle cell disease.

Authors:  Kim Smith-Whitley
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

8.  Sickle cell disease in adults: developing an appropriate care plan.

Authors:  Nadine Matthie; Coretta Jenerette
Journal:  Clin J Oncol Nurs       Date:  2015-10       Impact factor: 1.027

9.  Nurses' attitudes toward patients with sickle cell disease: a worksite comparison.

Authors:  Coretta M Jenerette; Bosny J Pierre-Louis; Nadine Matthie; Yasmeen Girardeau
Journal:  Pain Manag Nurs       Date:  2015-06       Impact factor: 1.929

Review 10.  Emerging point-of-care technologies for sickle cell disease screening and monitoring.

Authors:  Yunus Alapan; Arwa Fraiwan; Erdem Kucukal; M Noman Hasan; Ryan Ung; Myeongseop Kim; Isaac Odame; Jane A Little; Umut A Gurkan
Journal:  Expert Rev Med Devices       Date:  2016-11-22       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.